Clinical trial · Observational
CERvical Cancer The InFlammatory Index (CERTIFIKO)
CERvical Cance The InFlammatory Index as a Predictor of risK Stratification:an Observational Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Although significant advances in screening and treatment , cervical cancer is the fifth most common female cancer in Europe. Major prognostic factors for oncological outcome are used to categorise patients at high, intermediate and low risk groups and to define the type of radical hysterectomy according "Querleu-Morrow classification". The goal of this prospective observational study is to evaluate the association between several inflammatory markers and risk groups according European guidelines in women with cervical cancer Human Papillomavirus (HPV)-associated, in order to optimize the treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| biopsy | Procedure | — | UNRESOLVED |
| Venous blood sample | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cervical cancer patients
- description
- The population is represented by women being admitted to the Gynecology Ward who are affected by cervical cancer.
- interventionNames
- Diagnostic Test: Venous blood sample
- Procedure: biopsy
Primary outcomes (8)
- measure
- Grading
- timeFrame
- 30 days after surgery
- description
- Anatomic pathology report of cell anaplasia in the sampled tumor
- measure
- Staging
- timeFrame
- 30 days after surgery
- description
- Anatomic pathology report of extent to which the cancer has spread
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:
* At least 18-year-old patients.
* Patients histologically diagnosed with cervical cancer (squamous cell carcinoma or adenocarcinoma HPV- associated)
* Patients with (2018 FIGO) stage ≤ IB2 ("Early Cervical Cancer")
* Patients undergoing full-body CT-scan 30 days before enrollment.
Exclusion Criteria:
* Patients unfit to plead
* Patients with chronic inflammatory diseases (IBDs; rheumatic conditions)
* Synchronous tumors or cancer diagnosis in the previous 3 years
* Patients undergoing steroid therapy in the last 30 days prior to recruitmentReferences
Publications (1)
- DERIVEDRonsini C, Di Nuzzo A, Solazzo MC, Scaffa C, Ascione C, Chiantera V. Exploratory Analysis of Systemic Inflammatory Indices Across Locoregional Tumor Progression Parameters in Cervical Cancer: The CERTIFIKO Prospective Study. Medicina (Kaunas). 2026 Aug 17;62(8):1570. doi: 10.3390/medicina62081570. PMID 42654467